Aurobindo recalls more than 112,000 bottles of Amazon-brand acetaminophen over discolored caplets

Aurobindo Pharma USA has voluntarily recalled more than 112,000 bottles of Amazon's private-label Extra Strength Acetaminophen after customers reported finding discolored caplets inside sealed bottles, according to a recall record in the Food and Drug Administration's enforcement database. The recall, which the company began on Sept. 18, covers 200-count, 500-count and 1,000-count bottles of the 500-milligram caplets sold under Amazon's "amazon" and Amazon Basic Care house brands.

The recall sat largely unnoticed in the FDA's weekly recalls and safety alerts system for roughly three weeks before it was picked up broadly by national outlets on Oct. 13, prompting a wave of coverage reminding consumers to check their medicine cabinets.

The scope of the recall

The FDA's enforcement report puts the total at 112,932 bottles, broken down by package size. The bulk of the recalled product, 90,456 bottles, is in 500-count packaging distributed under NDC 72288-692-50, covering five separate lots with expiration dates ranging from Sept. 30, 2027, to Feb. 29, 2028. Another 14,640 bottles are 200-count packs under one lot expiring Sept. 30, 2027, and 7,836 bottles are 1,000-count packs under a single lot expiring Nov. 30, 2027, figures that are published in full on the FDA's weekly enforcement report page.

All of the product was made in India by Aurobindo Pharma USA Inc., whose American headquarters sits in East Windsor, New Jersey, and distributed nationwide by Amazon.com Services LLC under the retailer's Basic Care over-the-counter line, according to the National Library of Medicine's drug-listing record for the product. The recall does not extend to other acetaminophen strengths sold by Amazon or to any Tylenol-branded product. The FDA's record gives the reason for the action simply as consumer complaints of discoloration; it does not describe any reports of illness or injury tied to the tablets, and as of the agency's most recent update the recall remained listed as "not yet classified," meaning regulators have not yet assigned it a risk category.

A private label with a recurring problem

This is not the first time Aurobindo has pulled Amazon-branded acetaminophen for the same complaint. In May 2025 the company recalled 4,608 bottles of 325-milligram Amazon Basic Care acetaminophen tablets after shoppers reported "brown surface" discoloration; the FDA classified that recall Class II the following month, indicating a risk of temporary or reversible health effects. A year earlier, Aurobindo's AuroHealth division recalled a different Amazon-sold product, Healthy Living migraine relief tablets, after bottles went out missing their required drug-facts labeling.

The repeated issues come as Aurobindo's broader manufacturing network has drawn increased FDA scrutiny. In August, Eugia Pharma Specialities, an Aurobindo unit that makes sterile injectable drugs at a separate facility in India, received an FDA warning letter over manufacturing violations, following an "Official Action Indicated" finding at that plant. That facility makes different products than the recalled acetaminophen and the two matters are not formally linked, but together they add to a pattern of quality complaints trailing one of the largest suppliers of generic and store-brand medicines sold in the United States. Amazon's Basic Care line, launched in 2017 as the retailer's answer to drugstore house brands, has built a sizable share of online sales of over-the-counter pain relievers, antacids and allergy medicine by undercutting national brand prices; acetaminophen has consistently been one of its top-selling categories.

The repeated discoloration complaints also arrive as Amazon's broader medicine business faces separate federal scrutiny. The FDA has sent the company at least several warning letters since 2023 over unapproved drugs sold by outside sellers through its marketplace, including creams marketed for skin conditions that the agency said amounted to unapproved new drugs. Those letters involve third-party sellers rather than Amazon's own private-label products, and regulators have made clear that fulfillment through Amazon's own warehouses does not shield the company from responsibility for what third parties sell under its roof. The Basic Care acetaminophen at the center of this recall is a different arrangement entirely: Amazon owns the brand and contracts a manufacturer, in this case Aurobindo, to produce it, which is the same model used by most store brands sold in pharmacies and supermarkets. Still, the overlapping headlines have fed a broader conversation among consumer advocates about how closely any online retailer can vouch for the medicine it sells, whether branded as its own or resold by others.

What consumers should do

Anyone who bought Amazon-brand or Amazon Basic Care Extra Strength Acetaminophen 500 mg caplets in the affected package sizes is advised to compare the lot number and expiration date printed on the bottle against the FDA's listing before taking any more of the pills. The agency's standard guidance for this type of recall, repeated across the FDA's enforcement reports, directs consumers with questions about a specific lot to contact their pharmacist or health care provider rather than continue using tablets that look different from normal.

Unlike Aurobindo's 2024 recall of its migraine-relief product, this recall was not accompanied by a separate company announcement spelling out a refund process, and neither Aurobindo nor Amazon has issued a public statement beyond what appears in the FDA's enforcement record. That leaves open, for now, exactly how shoppers who bought the affected lots should seek a refund or replacement, beyond the general instruction to contact a pharmacist with questions about a specific bottle.

Acetaminophen is among the most widely used drugs in the country and is generally considered safe within labeled doses, but federal regulators have long warned that overdoses, whether accidental or from combining multiple acetaminophen-containing products, can cause severe liver damage. The FDA has previously estimated that unintentional acetaminophen overdoses contribute to tens of thousands of emergency room visits and several hundred deaths a year nationally. Discoloration on its own is not evidence of a dosing problem; pharmacists say a color change in a tablet more often points to chemical degradation from heat, light or moisture that can reduce a pill's potency, though the FDA has not described what, if anything, its testing found in the recalled lots beyond the discoloration itself.

The enforcement report lists the recall as "ongoing," and the FDA has not indicated when it expects to complete its classification review. A classification, when it comes, will determine how the agency formally describes the health risk: a Class I finding would mean the agency believes using the product could cause serious harm, Class II would indicate a temporary or reversible risk, and Class III would mean the violation is unlikely to cause any adverse health consequence. The company's 2025 discoloration recall of a different Amazon acetaminophen product was ultimately classified Class II, which may offer a rough guide to how regulators are likely to treat this one, though the FDA has given no indication of its thinking so far.

In the meantime, consumers can search the recalled lot numbers against the agency's public enforcement database, and both Aurobindo and Amazon can be reached through the contact channels listed on the recalled product's packaging for further guidance. Retail pharmacies that sell their own store-brand acetaminophen are not affected by this recall, which is limited to product sold through Amazon under the "amazon" and Amazon Basic Care labels.